The COVID-19 pandemic has disrupted the world like few events before it. But for Shukun Technology, a response required "a minor change in our strategy," according to its chief technology officer, Chao Zheng. That's because Shukun, a startup founded by some of China's brightest AI and medical minds, was busy refining its AI-powered platform to diagnose heart disease and strokes when the global pandemic struck. The company quickly shifted resources to develop a system that analyzes chest CT scans to help speed up diagnoses of COVID-19 patients. That system, called Lung Doc – pneumonia edition, has already been rolled out to 30 hospitals in China over the past few months, where it will grow more accurate as it learns from more data.
GE Healthcare officially launched the Edison AI platform in Shanghai, China at its Digital Ecosystem Forum event. GE also signed a Memorandum of Understanding (MoU) of strategic partnership with five local software development companies: Shukun Technology, Yizhun Medical AI, YITU Technology, 12Sigma Technologies and Biomind. Under the MoU, GE will cooperate with the five software vendors to develop the platform's applications in China. GE Healthcare's Edison platform was first introduced at last year's Radiological Society of North America annual meeting in Chicago in November. The platform is touted as a way to help hospitals derive more value from their technology.
Approvals for AI-based healthcare products are streaming in from regulators around the globe, with medical imaging leading the way. It's just the start of what's expected to become a steady flow as submissions rise and the technology becomes better understood. More than 90 medical imaging products using AI are now cleared for clinical use, thanks to approvals from at least one global regulator, according to Signify Research Ltd., a U.K. consulting firm in healthcare technology. Regulators in Europe and the U.S. are leading the pace. Each has issued about 60 approvals to date.
Roughly 600,000 people in China die from lung cancer every year. Already the leading cause of death in the pollution-choked and chain-smoking-prone nation, the incidence of lung cancer among China's citizens is actually going to increase to 800,000 cases per year by 2020. The situation has gotten bad enough that China's state media has not only been forced to report on the spread of cancer in the country, but also lay the blame squarely at the feet of the nation's runaway pollution problem. The issue is compounded by a lack of quality healthcare in much of the country, which means that cancers often go undetected until it's too late. For Chen Kuan, the chief executive and founder of Infervision, a Beijing-based company using machine learning and computer vision to help diagnose cancers, the problem isn't just academic.
HONG KONG, July 18 (Reuters Breakingviews) - Forget autonomous driving: The latest digital buzzword is medtech. Investors at last week's annual RISE technology conference in Hong Kong talked up a coming healthcare artificial-intelligence revolution, and the hype is as palpable in Silicon Valley. Chinese firms are well positioned to take the lead. Biometric and genome data - everything from blood pressure readings to tissue samples and DNA - are transforming the industry, from the way pharmaceutical firms discover drugs to how doctors diagnose patients. The hunt is on for better, and cheaper, treatments.